TW200507853A - Use of s-10-hydroxy-10,11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders - Google Patents

Use of s-10-hydroxy-10,11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders

Info

Publication number
TW200507853A
TW200507853A TW093103633A TW93103633A TW200507853A TW 200507853 A TW200507853 A TW 200507853A TW 093103633 A TW093103633 A TW 093103633A TW 93103633 A TW93103633 A TW 93103633A TW 200507853 A TW200507853 A TW 200507853A
Authority
TW
Taiwan
Prior art keywords
anxiety
treatment
enantiomer
carbamazepine
dihydro
Prior art date
Application number
TW093103633A
Other languages
English (en)
Inventor
Graeme Bilbe
John F Cryan
Conrad Gentsch
Kevin Hall Mcallister
Markus Schmutz
Annick Vassout
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0303613A external-priority patent/GB0303613D0/en
Priority claimed from GB0303614A external-priority patent/GB0303614D0/en
Priority claimed from GB0307281A external-priority patent/GB0307281D0/en
Priority claimed from GB0307278A external-priority patent/GB0307278D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TW200507853A publication Critical patent/TW200507853A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
TW093103633A 2003-02-17 2004-02-16 Use of s-10-hydroxy-10,11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders TW200507853A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0303613A GB0303613D0 (en) 2003-02-17 2003-02-17 Use of organic compounds
GB0303614A GB0303614D0 (en) 2003-02-17 2003-02-17 Use of organic compounds
GB0307281A GB0307281D0 (en) 2003-03-28 2003-03-28 Use of organic compounds
GB0307278A GB0307278D0 (en) 2003-03-28 2003-03-28 Use of organic compounds

Publications (1)

Publication Number Publication Date
TW200507853A true TW200507853A (en) 2005-03-01

Family

ID=32872853

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093103633A TW200507853A (en) 2003-02-17 2004-02-16 Use of s-10-hydroxy-10,11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders

Country Status (10)

Country Link
US (2) US7638510B2 (zh)
EP (1) EP1596866A2 (zh)
JP (1) JP2006517941A (zh)
AU (1) AU2004212328B2 (zh)
BR (1) BRPI0407569A (zh)
CA (1) CA2514649A1 (zh)
MX (1) MXPA05008729A (zh)
PL (1) PL376756A1 (zh)
TW (1) TW200507853A (zh)
WO (1) WO2004071152A2 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
KR101236227B1 (ko) * 2005-05-06 2013-02-21 바이알 - 포르텔라 앤드 씨에이 에스에이 에스리카르바제핀 아세테이트 및 그의 사용방법
GB0517740D0 (en) * 2005-08-31 2005-10-12 Novartis Ag Organic compounds
CA2651954C (en) * 2006-05-11 2014-02-25 Academia Sinica Hla alleles associated with adverse drug reactions and methods for detecting such
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
EP2747770A1 (en) * 2011-08-26 2014-07-02 BIAL - Portela & Cª S.A. Treatments involving eslicarbazepine acetate or eslicarbazepine
JP2013237676A (ja) * 2013-06-26 2013-11-28 Bial-Portela & Ca Sa 酢酸エスリカルバゼピン及び使用方法
JP2016047838A (ja) * 2015-11-05 2016-04-07 バイアル−ポルテラ アンド シーエー，エス．エー． 酢酸エスリカルバゼピン及び使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT101732B (pt) * 1995-06-30 1997-12-31 Portela & Ca Sa Novas di-hidrodibenzo<b,f>azepinas substituidas processo para a sua preparacao composicoes farmaceuticas que as contem e utilizacao dos novos compostos na preparacao de composicoes farmaceuticas empregues em doencas do sistema nervoso
DE60228988D1 (de) * 2001-11-12 2008-10-30 Novartis Ag Monohyroxycarbamezepin zur verwendung bei der herstellung eines medikaments zur behandlung von affektiver psychose, aufmerksamkeits störungen und neuropathischen schmerzen

Also Published As

Publication number Publication date
MXPA05008729A (es) 2005-09-20
WO2004071152A2 (en) 2004-08-26
CA2514649A1 (en) 2004-08-26
AU2004212328A1 (en) 2004-08-26
AU2004212328B2 (en) 2008-01-17
US20060194791A1 (en) 2006-08-31
US20100063029A1 (en) 2010-03-11
WO2004071152A3 (en) 2004-10-14
JP2006517941A (ja) 2006-08-03
EP1596866A2 (en) 2005-11-23
BRPI0407569A (pt) 2006-02-14
PL376756A1 (pl) 2006-01-09
US7638510B2 (en) 2009-12-29

Similar Documents

Publication Publication Date Title
NO20060847L (no) Substituert 2-aminotetralin til behandling av depresjon
TW200508180A (en) Therapeutic agents
PL1697370T3 (pl) Azabicykliczne heterocykle jako modulatory receptora kanabinoidowego
MY138252A (en) Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease
IS8503A (is) Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar
RU2008127882A (ru) Лечение пищевода барретта
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
NZ512526A (en) 4-sulfonamido-6-sulfamidoalkoxypyrimidine derivatives, pharmaceuticals thereof, and their use for the treatment of disorders associated with a role of endothelin.
TW200507853A (en) Use of s-10-hydroxy-10,11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders
HK1141019A1 (en) Carbamoyloxy arylalkanoyl arylpiperazine compound, pharmaceutical compositions comprising the compound and method for treating pain, anxiety and depression by administering the compound
DK1322305T3 (da) Anvendelse af R-arylpropionsyrer til fremstilling af lægemidler til behandling af lidelser af rheumatisk natur
SE0203300D0 (sv) Novel Compounds
HK1075894A1 (en) Prucalopride-n-oxide
CR7271A (es) Formulaciones farmaceuticas novedosas a base de melatonina y compuestos similares para su uso en transtornos del sueno
UA83870C2 (ru) Замещенные бицикло[3.1.1]гептаном производные бензимидазолона и хиназолинона как агонисты человеческих рецепторов orl1
SE0000303D0 (sv) Novel compounds
ATE430126T1 (de) Neue dibenzoäb,füoxepin-10-carbonsäureamide und deren pharmazeutische anwendungen
DE60228968D1 (de) Deramciclan-enthaltende pharmazeutische zusammensetzung für die behandlung der verringerung kognitiver funktionen und/oder schäden davon
SE0301885D0 (sv) New use IV
NZ512684A (en) Salts of (R)- or (S)-N-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide useful in treating central nervous system disorders
SE0203778D0 (sv) A new oral immediated release dosage form
ATE418973T1 (de) Spirocyclopropyl-amide und -säuren und ihre therapeutischen anwendungen
BR0212454A (pt) Composto, composição farmacêutica, métodos para o tratamento ou prevenção de distúrbios fisiológicos associados com um excesso de taquicininas e de dor ou inflamação, enxaqueca, êmese, neuralgia pós-terpética, depressão ou ansiedade, e, uso de um composto
ATE288753T1 (de) Verwendung von 3-(1h-imidazol-4-ylmethyl)-indan-5-ol zur herstellung eines medikamentes zur intraspinalen, intrathekalen und epiduralen anwendung
UA89236C2 (ru) Фармацевтическая композиция, которая содержит 1-( 3-хлорофенил)- 3-алкилпиперазин, для лечения нарушения аппетита